{"success":true,"data":{"pressRelease":{"id":"167431","rtpr_id":"nGNX3wz5pm-20261013","ticker":"MBX","exchange":"NASDAQ","all_tickers":["MBX"],"title":"MBX Biosciences to Participate in Upcoming November Investor Conferences","author":"Globe Newswire","published_at":"2026-10-13T12:00:00.936Z","article_body":"CARMEL, Ind. and BURLINGTON, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- MBX\nBiosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company\nfocused on the discovery, development and commercialization of novel precision\npeptide therapies for the treatment of endocrine and metabolic disorders,\ntoday announced that Steve Hoerter, Chairman and Chief Executive Officer, and\nSam Azoulay, M.D., Chief Medical Officer, will present at, and participate in,\nthe following upcoming investor conferences:\n\nGuggenheim 3rd Annual Healthcare Innovation Conference\nDate: Tuesday, November 10, 2026\nFormat: Fireside Chat and 1x1 meetings\nTime: 11:00 – 11:25 a.m. EST \nLocation: Boston, MA\n\nUBS Global Biopharma Conference\nDate: Tuesday, November 17, 2026\nFormat: Fireside Chat and 1x1 meetings\nTime: 8:00 – 8:30 a.m. GMT \nLocation: London, UK\n\nJefferies Global Healthcare Conference\nDate: Wednesday, November 18, 2026\nFormat: Fireside Chat and 1x1 meetings\nTime: 4:00 – 4:25 p.m. GMT \nLocation: London, UK\n\nThe live webcasts can be accessed in the events section of the MBX Biosciences\nwebsite at https://investors.mbxbio.com/news-events/events. Access to the\nwebcast replays will be available approximately two hours after the completion\nof the events and will be archived on the Company’s website for\napproximately 90 days.\n\nAbout MBX Biosciences\nMBX Biosciences is a biopharmaceutical company focused on the discovery,\ndevelopment and commercialization of novel precision peptide therapies based\non its proprietary PEP™ platform, for the treatment of endocrine and\nmetabolic disorders. The Company is advancing a pipeline of novel candidates\nfor endocrine and metabolic disorders with clinically validated targets,\nestablished endpoints for regulatory approval, significant unmet medical needs\nand large potential market opportunities. The Company’s pipeline includes\ncanvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism in\nPhase 3; and an obesity portfolio that includes MBX 4291 in Phase 1, and MBX\n5765 and MBX 6180 in preclinical development, as well as additional discovery\ncandidates. The Company is based in Carmel, Indiana and Burlington,\nMassachusetts. To learn more, please visit the Company website at\nwww.mbxbio.com and follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=rU153lCyn1aK0X9p4UvVS4QtpEOvC6ERl2dxom9SF04nS8nfnOQcZ0sAVnZmfczMtWcP0El6RSfEHXNrQg2yS-hH5HZTg4JrOozdMueioGrgAPGCWMJF7tOw9lurexgUP2pXeEQjDuziiyeG0aL_TQ17nVvBIX745cJSiX3q73ZFkUNWXMRCqucU0xlBEtL7ssq32xg5Mgsqab5c7CELyns4M62JFJXhExKcogDyVR1rkOqZn4Hwrlke3pmrT_5-I8Fh2qnmo7nNZSZVi0KBZg==)\nand X\n(https://www.globenewswire.com/Tracker?data=A0uSYsTBb9JvpSr6s1TFWo9RCktI9lDwD-DLIRk5zc2BHx9jN_IMWxRZw_oU0SO1OUI1ciOkxed06_3aSztjqzx7R9qQYnVCVvjSStvNr0gwVXCjSY6vaFeWZUU784Ha9Ow2Da0T6y65cDgS2mUuoAcbssm0IMK56YqSGrMBRgFeHBH-hdhENkxUPncgjz5O).\n\nMedia Contact:\nGeorge Shea\nWe. Communications\ngshea@wecommunications.com\n\nInvestor Contact:\nPete De Spain\nMBX Biosciences\npdespain@mbxbio.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/5499b327-bce0-4a3f-96a7-04a38b68a99f)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX3wz5pm-20261013","title":"MBX Biosciences to Participate in Upcoming November Investor Conferences","author":"Globe Newswire","ticker":"MBX","created":"2026-10-13T12:00:00.936Z","tickers":["MBX"],"exchange":"NASDAQ","article_body":"CARMEL, Ind. and BURLINGTON, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- MBX\nBiosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company\nfocused on the discovery, development and commercialization of novel precision\npeptide therapies for the treatment of endocrine and metabolic disorders,\ntoday announced that Steve Hoerter, Chairman and Chief Executive Officer, and\nSam Azoulay, M.D., Chief Medical Officer, will present at, and participate in,\nthe following upcoming investor conferences:\n\nGuggenheim 3rd Annual Healthcare Innovation Conference\nDate: Tuesday, November 10, 2026\nFormat: Fireside Chat and 1x1 meetings\nTime: 11:00 – 11:25 a.m. EST \nLocation: Boston, MA\n\nUBS Global Biopharma Conference\nDate: Tuesday, November 17, 2026\nFormat: Fireside Chat and 1x1 meetings\nTime: 8:00 – 8:30 a.m. GMT \nLocation: London, UK\n\nJefferies Global Healthcare Conference\nDate: Wednesday, November 18, 2026\nFormat: Fireside Chat and 1x1 meetings\nTime: 4:00 – 4:25 p.m. GMT \nLocation: London, UK\n\nThe live webcasts can be accessed in the events section of the MBX Biosciences\nwebsite at https://investors.mbxbio.com/news-events/events. Access to the\nwebcast replays will be available approximately two hours after the completion\nof the events and will be archived on the Company’s website for\napproximately 90 days.\n\nAbout MBX Biosciences\nMBX Biosciences is a biopharmaceutical company focused on the discovery,\ndevelopment and commercialization of novel precision peptide therapies based\non its proprietary PEP™ platform, for the treatment of endocrine and\nmetabolic disorders. The Company is advancing a pipeline of novel candidates\nfor endocrine and metabolic disorders with clinically validated targets,\nestablished endpoints for regulatory approval, significant unmet medical needs\nand large potential market opportunities. The Company’s pipeline includes\ncanvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism in\nPhase 3; and an obesity portfolio that includes MBX 4291 in Phase 1, and MBX\n5765 and MBX 6180 in preclinical development, as well as additional discovery\ncandidates. The Company is based in Carmel, Indiana and Burlington,\nMassachusetts. To learn more, please visit the Company website at\nwww.mbxbio.com and follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=rU153lCyn1aK0X9p4UvVS4QtpEOvC6ERl2dxom9SF04nS8nfnOQcZ0sAVnZmfczMtWcP0El6RSfEHXNrQg2yS-hH5HZTg4JrOozdMueioGrgAPGCWMJF7tOw9lurexgUP2pXeEQjDuziiyeG0aL_TQ17nVvBIX745cJSiX3q73ZFkUNWXMRCqucU0xlBEtL7ssq32xg5Mgsqab5c7CELyns4M62JFJXhExKcogDyVR1rkOqZn4Hwrlke3pmrT_5-I8Fh2qnmo7nNZSZVi0KBZg==)\nand X\n(https://www.globenewswire.com/Tracker?data=A0uSYsTBb9JvpSr6s1TFWo9RCktI9lDwD-DLIRk5zc2BHx9jN_IMWxRZw_oU0SO1OUI1ciOkxed06_3aSztjqzx7R9qQYnVCVvjSStvNr0gwVXCjSY6vaFeWZUU784Ha9Ow2Da0T6y65cDgS2mUuoAcbssm0IMK56YqSGrMBRgFeHBH-hdhENkxUPncgjz5O).\n\nMedia Contact:\nGeorge Shea\nWe. Communications\ngshea@wecommunications.com\n\nInvestor Contact:\nPete De Spain\nMBX Biosciences\npdespain@mbxbio.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/5499b327-bce0-4a3f-96a7-04a38b68a99f)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-13T12:00:01.157426805Z","server_sent_at_ms":1791892801157},"received_at":"2026-10-13T12:00:01.209Z","source_url":null},"analysis":{"id":"155735","press_release_id":"167431","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"MBX Biosciences announced that CEO Steve Hoerter and CMO Sam Azoulay will participate in three November investor conferences: Guggenheim Healthcare Innovation (Nov 10, Boston), UBS Global Biopharma (Nov 17, London), and Jefferies Global Healthcare (Nov 18, London).\n\nFireside chats and 1x1 meetings will be webcast live, with replays archived on the company's investor site for about 90 days.\n\nThe release contains no new clinical or financial data, though it recaps the pipeline including canvuparatide in Phase 3 for chronic hypoparathyroidism and an obesity portfolio led by MBX 4291 in Phase 1.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference calendar notice -- suppress unless webcast surfaces new data."},"keyFigures":{},"namedEntities":{"people":[{"name":"Steve Hoerter","role":"Chairman and CEO"},{"name":"Sam Azoulay, M.D.","role":"Chief Medical Officer"},{"name":"George Shea","role":"Media Contact, We. Communications"},{"name":"Pete De Spain","role":"Investor Contact, MBX Biosciences"}],"products":["canvuparatide (MBX 2109)","MBX 4291","MBX 5765","MBX 6180","PEP™ platform"],"companies":[{"name":"MBX Biosciences, Inc.","ticker":"MBX","relationship":"filer"},{"name":"Guggenheim","relationship":"conference host"},{"name":"UBS","relationship":"conference host"},{"name":"Jefferies","relationship":"conference host"},{"name":"We. Communications","relationship":"media relations agency"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement of investor conference participation with webcast details; no new data, results, or guidance disclosed."},"tickerRelevance":{"others":[],"primary":"MBX"},"globalImportance":8,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap-clinical-stage-biotech","eventGravity":"conference-schedule-notice","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"MBX Biosciences announced that CEO Steve Hoerter and CMO Sam Azoulay will participate in three November investor conferences: Guggenheim Healthcare Innovation (Nov 10, Boston), UBS Global Biopharma (Nov 17, London), and Jefferies Global Healthcare (Nov 18, London).\n\nFireside chats and 1x1 meetings will be webcast live, with replays archived on the company's investor site for about 90 days.\n\nThe release contains no new clinical or financial data, though it recaps the pipeline including canvuparatide in Phase 3 for chronic hypoparathyroidism and an obesity portfolio led by MBX 4291 in Phase 1.","key_figures":{},"named_entities":{"people":[{"name":"Steve Hoerter","role":"Chairman and CEO"},{"name":"Sam Azoulay, M.D.","role":"Chief Medical Officer"},{"name":"George Shea","role":"Media Contact, We. Communications"},{"name":"Pete De Spain","role":"Investor Contact, MBX Biosciences"}],"products":["canvuparatide (MBX 2109)","MBX 4291","MBX 5765","MBX 6180","PEP™ platform"],"companies":[{"name":"MBX Biosciences, Inc.","ticker":"MBX","relationship":"filer"},{"name":"Guggenheim","relationship":"conference host"},{"name":"UBS","relationship":"conference host"},{"name":"Jefferies","relationship":"conference host"},{"name":"We. Communications","relationship":"media relations agency"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-13T12:00:15.243Z","global_importance":8,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap-clinical-stage-biotech","eventGravity":"conference-schedule-notice","issuerAuthored":true}},"durationMs":4956,"modelName":"glm-5.3-flashx"}}